Crinetics Pharmaceuticals (CRNX) stock
NASDAQ
- Market cap
- Not available
- Date not confirmed
- P/E
- Not available
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
- Market cap
- Not available
- Date not confirmed
- P/E
- Not available
- Trailing twelve months
- P/B
- Not available
- Latest reported equity
- P/S
- Not available
- Trailing twelve months
- ROE
- Not available
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
Latest earnings
SEC filingsApr–Jun 2026(FY2026 Q2)
Revenue increased 2,400.0% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1M+2,400.0%
$1M
Apr–Jun '24
$1M
Apr–Jun '25
$25M
Apr–Jun '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Apr–Jun 2026 are from the 10-Q submitted to SEC EDGAR on Aug 3, 2026.
- Earnings per share increased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Revenue increased 2,400.0% from the same quarter a year earlier.
- Operating income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
- Net income decreased from a year earlier. The year-ago value was zero or negative, so no percentage change is shown.
Filed Aug 3, 2026 · 10-Q · SEC EDGAR
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- WIERENGA WENDELLDirector · Sep 1, 2026Disposition to the issuer122,071 shares · $10.4MAvg. price $85
Show 2 price lots
- 116,146 shares × $85$9.9M
- 5,925 shares × $85$504K
- Kalofonos IsabelChief Commercial Officer · Sep 1, 2026Disposition to the issuer35,669 shares · $3.0MAvg. price $85
Show 2 price lots
- 34,000 shares × $85$2.9M
- 1,669 shares × $85$142K
- Vivaldi Coelho RogerioDirector · Sep 1, 2026Disposition to the issuer19,225 shares · $1.6MAvg. price $85
Show 2 price lots
- 13,300 shares × $85$1.1M
- 5,925 shares × $85$504K
- Schilke TobinChief Financial & Infra. Ofcr. · Aug 20, 2026Grant or award471 shares · $0Avg. price $079,427 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Crinetics Pharmaceuticals (CRNX) stock information
NASDAQ
Crinetics Pharmaceuticals (CRNX) is listed on NASDAQ. These figures are computed in-house from official filings and are reference information only.
Crinetics Pharmaceuticals — frequently asked questions
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.